Screener / SEC EDGAR /CIK 0001157601 /10-K filed Feb 19, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Madrigal Pharmaceuticals, Inc. MDGL

Compare with peers Embed
FY2025 at a glance

Sales up 432.1%, free cash flow up to -$190.0M

XBRL, from each 10-K
RevenueStatements
$958.4M from $180.1M in FY2024
FY2016FY2025
Net incomeStatements
-$288.3M from -$465.9M in FY2024
FY2016FY2025
Free cash flowStatements
-$190.0M from -$457.0M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-12.85 from $-21.90 in FY2024
FY2016FY2025
Operating marginStatements
-31.3% from -276.4% in FY2024
FY2016FY2025
Total debtStatements
$339.9M from $117.6M in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (33)
EPS (ttm)
-8.05
Sales (ttm)
1.4B
Net income (ttm)
-155.5M
Sales growth
+432%
EPS growth
-
Sales Q/Q
+50.1%
Free cash flow
-168.7M
Gross margin
-
Oper. margin
-10.7%
Net margin
-10.9%
FCF margin
-11.8%
R&D / sales
40.5%
Dividend
-
Debt/Eq
0.54
Curr. ratio
3.05
Cash
514.6M
Op. cash flow (ttm)
-157.0M
EBITDA
-298.6M
EBITDA margin
-31.2%
Net debt
-173.4M
Quick ratio
2.89
Interest cover
-13.45
FCF after stock pay
-288.1M
Stock pay / sales
10.2%
Shares out.
23.2M
Shares Y/Y
+5.5%
Book / share
26.99
Cash / share
22.15
Sales / share
61.47
Asset turnover
1.00
Days sales out.
51

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2017 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 958.4M Net income -288.3M
FY2017 revenue 0 · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-20-049021 FY2017 net income -31.2M · NetIncomeLoss, 0001193125-20-049021 0 FY2017 FY2018 revenue 0 · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-21-056164 FY2018 net income -32.8M · NetIncomeLoss, 0001193125-21-056164 0 FY2018 FY2019 revenue 0 · Revenues, 0001193125-22-051569 FY2019 net income -83.9M · NetIncomeLoss, 0001193125-22-051569 0 FY2019 FY2020 revenue 0 · Revenues, 0001193125-22-051569 FY2020 net income -202.2M · NetIncomeLoss, 0001193125-23-060052 0 FY2020 FY2021 revenue 0 · Revenues, 0001628280-24-007376 FY2021 net income -241.8M · NetIncomeLoss, 0001628280-24-007376 0 FY2021 FY2022 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-25-007980 FY2022 net income -295.4M · NetIncomeLoss, 0001628280-25-007980 0 FY2022 FY2023 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-009514 FY2023 net income -373.6M · NetIncomeLoss, 0001628280-26-009514 0 FY2023 FY2024 revenue 180.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-009514 FY2024 net income -465.9M · NetIncomeLoss, 0001628280-26-009514 180.1M FY2024 FY2025 revenue 958.4M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001628280-26-009514 FY2025 net income -288.3M · NetIncomeLoss, 0001628280-26-009514 958.4M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +11.6% a year FY2020 $15.54 to FY2025 $26.86, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$12.85$26.86-$8.47
Dec 31, 2024 -$21.90$35.46-$21.48
Dec 31, 2023 -$19.99$21.69-$17.43
Dec 31, 2022 -$17.23$11.52-$13.13
Dec 31, 2021 -$14.63$11.86-$11.14
Dec 31, 2020 -$13.09$15.54-$10.22
Dec 31, 2019 ---
Dec 31, 2018 ---
Dec 31, 2017 ---
Dec 31, 2016 ---
Dec 31, 2015 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.2B
  • − All liabilities $656.9M
  • = Net current asset value $588.9M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $602.7M
  • − Other intangible assets $7.4M
  • = Tangible book value $595.3M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

MDGL against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+432%1st of 155 · median +10.5%
Net margin
-4.1%15.3%
-10.9%124th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-24.8%121st of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-11.8%123rd of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.5439th of 108 · median 0.69
MDGL and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
MDGL Madrigal Pharmaceuticals, Inc.$1.4B +432%--10.9%-24.8%-11.8%0.54
INSM INSMED Inc$1.5B +66.7%84.4%-39.9%-83.4%-41.3%0.75
LIVN LivaNova PLC$1.5B +10.7%67.8%13.0%14.3%8.6%0.22
ADUS Addus HomeCare Corp$1.5B +23.2%32.3%7.4%9.4%9.6%0.02
HAE Haemonetics Corp$1.4B -2.0%59.6%7.5%11.6%21.6%1.27
PGNY Progyny, Inc.$1.3B +10.4%24.9%6.8%22.0%13.4%-
All 162 companies in the group

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2024 · 10-K XBRL, year-end balances

Return on equity -47.8% FY2024: -61.8% net income ÷ equity
Net margin -30.1% FY2024: -258.6% profit per $ of sales: -288.3M ÷ 958.4M
Asset turnover 0.76× FY2024: 0.17× sales per $ of assets: 958.4M ÷ 1.3B
Leverage 2.09× FY2024: 1.38× assets per $ of equity: 1.3B ÷ 602.7M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -10.9% vs 6.8%
  • Return on equity below 15%
    -24.8%
  • A profit in 0 of 9 years
Net margin, FY2017 to FY2025: -258.6% to -30.1%

Balance sheet

  • Interest covered less than 5 times
    Operating income is -13.5× interest expense
  • Debt smaller than equity
    Debt / equity 0.54 on the latest balance sheet (peer median 0.69)
  • Current assets cover current liabilities
    Current ratio 3.05
  • More cash than debt
    Net cash $958.2M
Debt / equity at each year end, FY2017 to FY2025: 0.00 to 0.56

Cash and shareholders

  • Free cash flow positive in 0 of 9 years
    −$190.0M last year
  • Share count up over 5 years
    +45.2%
Free cash flow, FY2017 to FY2025: -22.4M to -190.0M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

$461.0M of principal due, schedule of Sep 30, 2026

Debt

Repayment schedule

From the balance sheet in the latest 10-K or 10-Q (XBRL). When each part falls due, year by year, and the debt note's own lines are on the Debt tab.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

MDGL's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue958.4M
FY2016: -FY2017: 0FY2018: 0FY2019: 0FY2020: 0FY2021: 0FY2022: 0FY2023: 0FY2024: 180.1MFY2025: 958.4M FY2017FY2019FY2021FY2023FY2025
Net income-288.3M
FY2016: -26.4MFY2017: -31.2MFY2018: -32.8MFY2019: -83.9MFY2020: -202.2MFY2021: -241.8MFY2022: -295.4MFY2023: -373.6MFY2024: -465.9MFY2025: -288.3M FY2017FY2019FY2021FY2023FY2025
Free cash flow-190.0M
FY2016: -17.6MFY2017: -22.4MFY2018: -25.5MFY2019: -41.8MFY2020: -157.9MFY2021: -184.1MFY2022: -225.1MFY2023: -325.7MFY2024: -457.0MFY2025: -190.0M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-288.1M
FY2016: -25.5MFY2017: -25.7MFY2018: -39.0MFY2019: -64.6MFY2020: -178.6MFY2021: -211.0MFY2022: -256.7MFY2023: -375.4MFY2024: -536.9MFY2025: -288.1M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-12.85
FY2016: -5.07FY2017: -2.54FY2018: -2.22FY2019: -5.45FY2020: -13.09FY2021: -14.63FY2022: -17.23FY2023: -19.99FY2024: -21.90FY2025: -12.85 FY2017FY2019FY2021FY2023FY2025
Diluted shares22.4M
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: 15.4MFY2021: 16.5MFY2022: 17.1MFY2023: 18.7MFY2024: 21.3MFY2025: 22.4M FY2017FY2019FY2021FY2023FY2025

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue-0000000180.1M958.4M
Cost of revenue------006.2M-
R&D15.9M24.4M25.4M72.3M184.8M205.2M245.4M272.4M236.7M388.5M
SG&A9.3M7.7M15.3M22.6M21.9M37.3M48.1M108.1M435.1M813.8M
Operating income-25.2M-32.1M-40.7M-95.0M-206.7M-242.5M-293.6M-380.5M-497.9M-300.1M
Interest expense1.2M---004.0M12.7M14.7M22.3M
Pretax income--------373.6M-465.9M-158.5M
Income tax--00000000
Net income-26.4M-31.2M-32.8M-83.9M-202.2M-241.8M-295.4M-373.6M-465.9M-288.3M
EPS (diluted)-5.07-2.54-2.22-5.45-13.09-14.63-17.23-19.99-21.90-12.85
Diluted shares----15.4M16.5M17.1M18.7M21.3M22.4M
Depreciation & amortization15677K96K112K471K405K467K527K1.1M1.5M
EBITDA-25.2M-32.0M-40.6M-94.9M-206.2M-242.1M-293.1M-380.0M-496.8M-298.6M
Operating margin---------276.4%-31.3%
Net margin---------258.6%-30.1%
Revenue growth---------+432%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-17.6M-22.3M-25.5M-41.6M-157.6M-183.9M-224.9M-324.2M-455.6M-189.6M
Capital spending3K125K22K172K334K209K217K1.5M1.5M467K
Free cash flow-17.6M-22.4M-25.5M-41.8M-157.9M-184.1M-225.1M-325.7M-457.0M-190.0M
Stock-based pay (added back)7.9M3.3M13.5M22.8M20.7M26.9M31.6M49.7M79.9M98.1M
Free cash flow after stock pay-25.5M-25.7M-39.0M-64.6M-178.6M-211.0M-256.7M-375.4M-536.9M-288.1M
Investing cash flow22.0M-22.0M-380.1M30.7M159.8M-5.1M206.7M-502.5M-274.4M32.3M
Financing cash flow14.5M173.8M314.3M235K5.1M171.2M313.5M595.1M735.1M256.0M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)7.9M3.3M13.5M22.8M20.7M26.9M31.6M49.7M79.9M98.1M
Stock-based pay / revenue--------44.3%10.2%
Operating lease cost---386K300K400K800K1.1M900K1.9M
Operating lease cash paid------700K1.1M1.1M1.4M
Right-of-use assets---675K785K797K602K1.7M2.4M4.9M
Operating lease liabilities---676K786K797K602K1.7M2.0M7.7M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MDGL/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.